A study by Israeli pharmaceutical company, Teva, has shown that its drug Copaxone, is effective not only for treating multiple sclerosis, but in preventing or delaying its progress. The study was cut short so that patients in the placebo group could be immediately given Copaxone.
Teva announced the positive results on Tuesday, which showed that treatment with Copaxone reduced the risk of developing clinically definite MS by 44% versus the placebo. Copaxone is the only relapsing-remitting MS treatment which demonstrates that among those continuing therapy with the drug, 92% still walk unassisted after 10 years of therapy and 18 years of disease duration.
Teva plans to request marketing authorization of Copaxone in Europe, the US, and Canada for the treatment of patients with a first clinical event suggestive of multiple sclerosis.